MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Bristol-Myers Squibb Co.

Geschlossen

BrancheGesundheitswesen

57.76 -3.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

57.75

Max

60.69

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.1B

76M

Verkäufe

442M

12B

KGV

Branchendurchschnitt

14.05

63.778

EPS

1.67

Dividendenrendite

4.07

Gewinnspanne

0.616

Angestellte

34,100

EBITDA

-1.9B

2.6B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+2.23% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.07%

2.39%

Nächstes Ergebnis

24. Apr. 2025

Nächste Dividendenausschüttung

1. Mai 2025

Nächstes Ex-Dividendendatum

4. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

311M

121B

Vorheriger Eröffnungskurs

60.81

Vorheriger Schlusskurs

57.76

Nachrichtenstimmung

By Acuity

33%

67%

94 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Bristol-Myers Squibb Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. März 2025, 10:13 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11. März 2025, 10:13 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6. Feb. 2025, 12:13 UTC

Ergebnisse

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14. März 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11. März 2025, 02:26 UTC

Akquisitionen, Fusionen, Übernahmen

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11. März 2025, 02:26 UTC

Akquisitionen, Fusionen, Übernahmen

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11. März 2025, 02:26 UTC

Akquisitionen, Fusionen, Übernahmen

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11. März 2025, 02:23 UTC

Akquisitionen, Fusionen, Übernahmen

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11. März 2025, 02:22 UTC

Akquisitionen, Fusionen, Übernahmen

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11. März 2025, 02:21 UTC

Akquisitionen, Fusionen, Übernahmen

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11. März 2025, 02:21 UTC

Akquisitionen, Fusionen, Übernahmen

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11. März 2025, 02:19 UTC

Akquisitionen, Fusionen, Übernahmen

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6. Feb. 2025, 15:35 UTC

Ergebnisse

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6. Feb. 2025, 13:56 UTC

Ergebnisse

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6. Feb. 2025, 13:25 UTC

Top News
Ergebnisse

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6. Feb. 2025, 12:00 UTC

Ergebnisse

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol-Myers Squibb 4Q Net $72M >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol-Myers Squibb 4Q EPS 4c >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6. Feb. 2025, 11:59 UTC

Ergebnisse

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Peer-Vergleich

Kursveränderung

Bristol-Myers Squibb Co. Prognose

Kursziel

By TipRanks

2.23% Vorteil

12-Monats-Prognose

Durchschnitt 60.93 USD  2.23%

Hoch 70 USD

Tief 37 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bristol-Myers Squibb Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

16 ratings

5

Buy

10

Halten

1

Sell

Technischer Score

By Trading Central

59.46 / 61.05Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

94 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.